12
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before July 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Hyperpyrexia, Allergic-Type Response and Death occurring with Low-Dose Bleomycin Administration

      case-report
      ,
      Oncology
      S. Karger AG
      Hyperpyrexia, Bleomycin, Mycosis fungoides

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This is a case report of hyperpyrexia, shock and death following initial injection of low-dose bleomycin (7.5 units) for a poorly differentiated metastatic carcinoma. Premedication with high-dose dexamethasone and acetamiophen did not abort the reaction. A review of the literature uncovered one nearly fatal reaction to a test dose of 1 unit of bleomycin. All previously reported fatal cases were in patients with lymphoma who had received an initial dose of at least 25 units/m<sup>2</sup>. Since the ‘safe’ test dose of bleomycin is not known, test doses of 1 unit or lower should be routinely used; the effect of premedication is also unclear.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          1980
          1980
          10 June 2009
          : 37
          : 5
          : 316-317
          Affiliations
          Sections of Neurology and Dermatology, Dartmouth-Hitchcock Medical Center, Hanover, N.H.
          Article
          225462 Oncology 1980;37:316–317
          10.1159/000225462
          6160440
          487bbefe-04a2-4836-aca7-6d9e3233be85
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 2
          Categories
          Original Paper

          Oncology & Radiotherapy,Pathology,Surgery,Obstetrics & Gynecology,Pharmacology & Pharmaceutical medicine,Hematology
          Bleomycin,Hyperpyrexia,Mycosis fungoides

          Comments

          Comment on this article